Travere Therapeutics (TVTX) PT Lowered to $35 at Evercore ISI
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/9/2026
- Wall Street set for weekly gains with earnings, inflation data on tap
- Oil falls as Trump comments on Iran talks ease supply fears
- Apple cuts iPhone 18 Pro orders due to soft demand, Nikkei Asia reports
- UBS flags level in gold prices where dip buyers will likely emerge
- Telecom stocks tumble on SpaceX spectrum acquisition news
Tweet
Share
E-mailGet Alerts TVTX Hot Sheet
Price: $52.31 +0.52%
Rating Summary:
12 Buy, 2 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 10 | Down: 14 | New: 37
Rating Summary:
12 Buy, 2 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 10 | Down: 14 | New: 37
Join SI Premium – FREE
Evercore ISI analyst Gavin Clark-Gartner lowered the price target on Travere Therapeutics (NASDAQ: TVTX) to $35.00 (from $45.00) while maintaining a Outperform rating.
You May Also Be Interested In
- Teva Pharma (TEVA) PT Raised to $52 at Oppenheimer
- Amrize Ltd (AMRZ) PT Lowered to $32 at RBC Capital
- Aspeed Technology Inc (5274:TT) PT Raised to NT$20,000 at Macquarie
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
